Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

30/03/2015
Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds

Abstract Transmission of drug-resistant pathogens presents an almost-universal challenge for fighting infectious diseases. Transmitted drug resistance mutations (TDRM) can persist in the absence of drugs for considerable time. It is generally believed that differential TDRM-persistence is caused, at least partially, by variations in TDRM-fitness-costs. However, in vivo...

Read more...

Source Source: PLOS Pathogens





30/03/2015
Immune Response BioPharma, Inc. announces the FDA has accepted the Remune HIV/AIDS vaccine BLA for review

New York, NY, March 29, 2015 -- Immune Response BioPharma, Inc., today provides an update on Remune and announces the FDA has accepted the Remune HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS. The FDA review period for the Remune HIV/AIDS vaccine BLA begins on March 27th 2015. Remune is a therapeutic vaccine...

Read more...





30/03/2015
Japan’s Ministry of Health, Labour and Welfare approves Gilead’s Sovaldi® (sofosbuvir) for the treatment of genotype 2 chronic hepatitis C

Sovaldi part of first all-oral treatment regimen for genotype 2 patients in Japan 96 percent cure rates and shortened, 12-week course of therapy FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 26, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Sovaldi® (sofosbuvir), a once-daily...

Read more...





30/03/2015
Cipla announces the launch of generic drug sofosbuvir in India under the brand name ‘Hepcvir’

Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug sofosbuvir available to Indian patients. Read the press release here.

Read more...

Source Source: Cipla Limited





30/03/2015
HIV can spread early, evolve in patients’ brains

Findings add urgency to screening, treatment – NIH-funded study The AIDS virus can genetically evolve and independently replicate in patients’ brains early in the illness process, researchers funded by the National Institutes of Health have discovered. An analysis of cerebral spinal fluid (CSF), a window into brain chemical activity, revealed that for a subset of...

Read more...